Coherus Biosciences | CHRS - Cash And Equivalent


Coherus Biosciences reported $88.88M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Akebia Therapeutics USD 184.84M 18.4M Dec/2025
ALKERMES USD 388.57M 227.88M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amarin USD 122.8M 25.08M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Baxter International USD 1.97B 240M Dec/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Fujifilm JPY 160.88B 906M Sep/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
Ironwood Pharmaceuticals USD 140.41M 47.56M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Myriad Genetics USD 149.6M 4.2M Dec/2025
Pacira USD 158.54M 10.96M Dec/2025
Perrigo USD 432.1M 22.1M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025
Xencor USD 54.07M 25.78M Dec/2025
Zoetis USD 2.08B 649M Sep/2025